Status: Not yet recruiting
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront microbiological confirmed diagnosis
Participants needed: 165
Trial details
Phase: Phase 1, Phase 2Age: 18-50Biological sex: FemaleType: InterventionalSponsor: NEXBIOME THERAPEUTICSUpdated: Jun 12, 2024
Eligibility criteria
Post-menarche woman aged 18 to 50 years old (inclusive), [+3]
Other already diagnosed or suspected infectious causes of bacterial vaginal infe... [+11]